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ABSTRACT
Objectives: Thrombocytopenia is defined as a platelet count of < 150 × 109/L. It is a common hematologic abnormality 
during pregnancy. Evaluation and treatment of gestational thrombocytopenia can be both, expensive and invasive, and 
may result in an adverse outcome. The aim of our study was to investigate the incidence of perinatal complications in 
pregnancies complicated with gestational thrombocytopenia and to determine if the severity of maternal gestational 
thrombocytopenia implicates unfavorable perinatal outcome. 
Material and methods: Over a period of three years, we identified 50 patients with gestational thrombocytopenia: 
38 with platelet count between 50–100 × 109/L — classified as moderate thrombocytopenia, and 12 with platelet count 
of < 50 × 109/L — classified as severe thrombocytopenia. Fifty women with normal platelet count constituted the control 
group. Maternal complications and neonatal outcomes were compared. 
Results: Neonatal thrombocytopenia occurred more often in pregnancies complicated with gestational thrombocytopenia 
(p = 0.041). Thrombocytopenia in previous pregnancy seems to be an important predicting factor for disease severity in 
the current pregnancy (p = 0.01).
Conclusions: Gestational thrombocytopenia, even if severe, is not associated with adverse maternal or neonatal outcome. 
Moderate neonatal thrombocytopenia is more common in pregnancies complicated with severe gestational thrombocy-
topenia. The incidence of severe gestational thrombocytopenia is higher in patients with thrombocytopenia in previous 
pregnancy.
Key words: gestational thrombocytopenia, neonatal thrombocytopenia, perinatal outcome, platelet count
Ginekologia Polska 2016; 87, 6: 454–459
Corresponding author:
Petrana Beljan
Department of Obstetrics and Gynecology, School of Medicine, University of Zagreb, Petrova 3,10 000 Zagreb, Croatia
e-mail: p.beljan@yahoo.com
INTRODUCTION
Thrombocytopenia affects 6.6–11.6% of all pregnancies 
[1]. It is the second most common hematologic abnormal-
ity during pregnancy but it is usually a benign condition. 
Thrombocytopenia in pregnancy can be isolated or asso-
ciated with systemic disorders like severe preeclampsia, 
HELLP syndrome (hemolysis, elevated liver enzymes, low 
platelets), or AFLP (acute fatty liver of pregnancy) [1]. Fur-
thermore, autoimmune diseases, including systemic lupus 
erythematosus, antiphospholipid syndrome, thrombotic 
thrombocytopenic purpura, hemolytic uremic syndrome, 
and immune thrombocytopenia (ITP) may relapse or be first 
detected during pregnancy. 
Major mechanisms for thrombocytopenia are decreased 
production and increased destruction of platelets, plate-
let sequestration, and hemodilution. Thrombocytopenia 
may also be the primary manifestation of viral infections 
(HIV, EBV, CMV), or a common adverse reaction from many 
drugs (heparin, antibiotics, nonsteroidal anti-inflamma-
tory drugs, diuretics). Magannet and Martin [2], classified 
thrombocytopenia according to its severity into: mild 
(100 to < 150 × 109/L), moderate (50 to < 100 × 109/L), 
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and severe (< 50 × 109/L). There are no diagnostic tests for 
gestational thrombocytopenia. The disease is diagnosed 
by exclusion and is defined by the platelet count of no less 
than 70x109/L, with the count returning to normal within 
12 weeks after delivery [3]. 
Increased blood volume, increased platelet activation, 
and increased platelet clearance contribute to a ‘physiologic’ 
decrease in platelet count during pregnancy [4]. Gestational 
thrombocytopenia is considered to be the most prevalent 
cause of thrombocytopenia in pregnancy and accounts for 
about 75% of cases its cases during pregnancy. The disease 
tends to occur late, usually during the third trimester [5, 6]. 
Whereas it is commonly believed that the prognosis for mild 
thrombocytopenia is most often favorable, we decided to 
focus on moderate and severe thrombocytopenia and their 
impact on the pregnancy outcome. 
Differentiating gestational thrombocytopenia from 
immune thrombocytopenia during pregnancy is clinically 
relevant, because pregnancies in women with immune 
thrombocytopenia may be complicated by severe neona-
tal thrombocytopenia, with a risk of neonatal intracranial 
hemorrhage [7, 8]. Our study was carried out to investigate 
the incidence of perinatal complications in pregnancies 
complicated with gestational thrombocytopenia and to 
define if the severity of maternal gestational thrombocyto-
penia implicates unfavorable perinatal outcome.
MATERIAL AND METHODS
This retrospective case-control study was conducted at 
the Department of Obstetrics and Gynecology, School of 
Medicine, University of Zagreb. Data for the study were col-
lected from all patients with gestational thrombocytopenia 
during a-3-year period (from January 2011 to December 
2013). We analyzed the platelet count of all singleton de-
liveries after 28 weeks of gestation (according to the last 
menstrual period or first trimester fetal ultrasonography). 
Pregnancies complicated with fetal structural or chromo-
somal anomalies, preexisting maternal diseases (diabetes 
mellitus, liver or renal diseases, blood count diseases, im-
mune thrombocytopenia known before pregnancy, sys-
temic lupus erythematosus), and gestational hypertensive 
diseases (preeclampsia, HELLP syndrome, eclampsia) were 
excluded from the study. 
Fifty women constituting the study group had negative 
anti-thrombocyte antibodies and gestational thrombocyto-
penia with the platelet count of < 100 × 109/L. Out of them, 
38 subjects had a platelet count between 50–100x109/L 
and were classified as having moderate thrombocytopenia. 
Twelve women from the study group had the platelet count 
of < 50 × 109/L and were classified as having severe throm-
bocytopenia. Fifty women with normal platelet count were 
recruited as controls. The control group included healthy 
pregnant women, matched for parity and gestational age 
with the study group. 
The following characteristics were compared: mode of 
delivery, thrombocytopenia in previous pregnancy, infec-
tion during pregnancy (significant bacteriuria/microbiologi-
cally positive cervical smear), placental abruption, and severe 
postpartum bleeding. Fetal outcomes were compared with 
regard to birth weight, neonatal acidosis (pH from umbilical 
vein < 7.20), Apgar scores at 1 and 5 minutes, admission to the 
Neonatal Intensive Care Unit (NICU), neonatal thrombocyto-
penia (platelet count of < 150 × 109/L), intrauterine growth re-
striction (fetal weight below the 10th percentile for gestational 
age), and stillbirth. Newborns weighing < 2500 grams were 
classified as ‘low birth weight’. Platelet counts of all newborns 
were observed in the first 48 hours postpartum. Statistical 
analysis was performed using SPSS version 20 (SPSS Inc., Chi-
cago, IL, USA). Nominal variables were expressed by count and 
percentage. Descriptive statistics were computed for continu-
ous and categorical variables. Frequencies are presented for 
the categorical variables between the study groups. We used 
the two sample t-test for continuous variables. Categorical 
variables between the groups were analyzed using the χ2-test 
or Fisher’s exact test. We used the logistic regression model 
to assess the independence of specific perinatal outcome 
parameters from prognostic factors. The logistic regression 
model was used to assess the independence of specific peri-
natal outcome parameters from the prognostic factors. The 
p-value of < 0.05 was considered as statistically significant.
RESULTS
No differences in the proportion of term deliveries and 
gestational age at delivery were observed. Thrombocyto-
penia in pregnancy did not affect the mode of delivery and 
preterm delivery rate. Cesarean section was performed in 
18 patients (36%) from the study group and 11 patients 
(22%) from the control group (p = 0.137) (Table 1). 
Only 1 case of postpartum hemorrhage was found in 
the patient with severe gestational thrombocytopenia, and 
1 case of placental abruption in the patient with moderate 
gestational thrombocytopenia (platelet count of < 83 × 109). 
Infection during pregnancy was significantly higher in the 
study group as compared to controls (p = 0.046) (Table 2). 
The incidence of neonatal thrombocytopenia was sig-
nificantly higher in the study group (p=0.041). Also, we 
found a higher admission rate to NICU (p = 0.153), IUGR 
(p = 0.40), acidosis (p = 0.558), and low birth weight neo-
nates (p = 0.081) in the study group (Figure 1).
In the study group, 38 women had moderate gesta-
tional thrombocytopenia (platelet count of 50–100 × 109/L) 
and 12 patients had severe gestational thrombocytopenia 
(platelet count of < 50 × 109/L). Two patients with severe 
thrombocytopenia in the current pregnancy (6.6%) had 
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Table 1. Maternal characteristics and pregnancy outcome
Characteristics
STUDY
group
(n = 50)
CONTROL
group
(n = 50)
P-value
Thrombocytopenia in previous pregnancy 2 (4%) 0 0.153
Infection during pregnancy* 8 (16%) 2(4%) 0.046
Gestational age (week) 38 (33–41) 39 (36–42) 0.634
Placental abruption 1 (2%) 0 0.315
Preterm delivery 5 (10%) 2 (4%) 0.240
Postpartum hemorrhage 1 (2%) 0 0.315
Cesarean section 18 (36%) 11 (22%) 0.137
Fetal demise in utero 1 (2%) 0 0.315
*Significant bacteriuria/microbiologically positive cervical smear; data are expressed as median or n (%). Study group: platelet count < 100 × 109/L. Control group: 
platelet count >150 × 109/L
Table 2. Fetal outcome
Outcome parameter
STUDY
group
(n = 50)
CONTROL
group
(n = 50)
P-value
Umbilical vein pH < 7.20 2 (4%) 1 0.558
1-min. Apgar score < 7 2 (4%) 1 (2%) 0.558
5-min. Apgar score < 7 2 (4%) 0 0.153
Low birth weight (< 2500 g) 7 (14%) 2 (4%) 0.081
Neonatal thrombocytopenia 4 (8%) 0 0.041
Admission to NICU 2 (4%) 0 0.153
IUGR 4 (8%) 2(4%) 0.40
Neonatal death 0 0 –
ICH 0 0 –
Data are expressed as median or n (%). Study group: platelet count < 100 × 109/L. Control group: platelet count > 150 × 109/L. NICU — neonatal intensive care unit; 
IUGR — intrauterine growth restriction; ICH — intracranial hemorrhage
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Figure 1. Pregnancy outcome with regard to severity of gestational thrombocytopenia
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thrombocytopenia in their previous pregnancies. Throm-
bocytopenia in previous pregnancy seems to be a valuable 
predictive factor for determining the severity of thrombocy-
topenia in the current pregnancy (p = 0.01). Corticosteroid 
therapy (oral prednisone) was used in 4 patients with severe 
thrombocytopenia (33.3%, p = 0.027), and transfusion with 
packed platelet cells in 2 patients from the same group 
(16.6%, p = 0.01). We found significantly higher rate of neo-
natal thrombocytopenia (p = 0.041) in patients with severe 
gestational thrombocytopenia (Table 3).
We detected a significant influence of severe gesta-
tional thrombocytopenia on neonatal Apgar score at 1 min. 
(p = 0.043) and high impact on neonatal acidosis (p = 0.078).
DISCUSSION
The most common cause of thrombocytopenia in preg-
nancy is gestational thrombocytopenia, which accounts for 
almost 75% of all cases [5]. The exact cause of gestational 
thrombocytopenia remains unclear, although it might be 
secondary to accelerated platelet consumption and in-
creased plasma volume associated with pregnancy [8]. 
About 70–80% of thrombocytopenia cases in pregnancy are 
due to gestational thrombocytopenia, typically with a plate-
let count of > 70 × 109/L, but a platelet count of < 70 × 109/L 
warrants an investigation for an alternative etiology [5, 7]. 
In our study group, 12 patients with severe gestational 
thrombocytopenia and a platelet count of < 50 × 109/L 
had negative tests for anti-platelet antibodies, so we classi-
fied them as severe gestational thrombocytopenia. Similar 
results were reported by Karim and Sacher [9], who docu-
mented the prevalence of severe thrombocytopenia in less 
than 0.1% pregnancies. As we enrolled only patients with 
a platelet count of < 100 × 109/L in our study group, the 
prevalence of gestational thrombocytopenia in our case 
was 0.4%, whereas most studies accepted a platelet count 
of < 150 × 109/L as the cut-off for gestational thrombocyto-
penia, thus having higher prevalence [5]. This variance might 
be due to the exclusion of women with major systemic 
diseases, as well as those with gestational hypertensive 
diseases and other pregnancy-related disorders. 
A platelet count of <100 × 109/L, the definition for throm-
bocytopenia adopted by the International Working Group 
[10], is observed in only 1% of pregnant women. Dwivedi et 
al. [11], observed a prevalence of 8.17%, with 4.08% having 
severe thrombocytopenia in their study. The frequency of ges-
tational thrombocytopenia in the largest series of consecutive 
women admitted for labor and delivery is 5%. Comparing the 
neonatal outcome, we found no significant differences in the 
incidence of neonatal acidosis or Apgar scores between the 
groups. However, we observed mild neonatal thrombocyto-
penia (> 100 × 109/L) (p < 0.041) in 4 neonates (8%) from our 
patients with gestational thrombocytopenia, with no other 
complications or need for admissions to the NICU. Ruggeri 
[12], reported a study of 41 pregnancies with gestational 
thrombocytopenia and found 2 infants with mild thrombo-
cytopenia and 1 with severe thrombocytopenia, whereas 
none had clinically important bleeding. Burrows and Kelton 
[5], also found that moderate and severe fetal thrombocy-
topenia are a rare occurrence. In their prospective cohort 
study of 756 women with gestational thrombocytopenia, 
none of their patients and only 1 infant, who had congenital 
bone marrow dysfunction diagnosed later, had any bleeding 
complications [5]. 
In a study by Nagey et al. [13], 7 out of 730 pregnancies 
had platelet counts of < 150 × 109/L, no neonate had a plate-
let count of < 100 × 109/L, and no bleeding complications 
were observed. We found no specific possible predictors for 
this outcome that would be significant in the available lit-
erature (Table 3). There is no consistent correlation between 
the incidence of neonatal thrombocytopenia and the sever-
ity of maternal thrombocytopenia [5, 14, 15]. According to 
the earlier studies, history of thrombocytopenia in an older 
sibling is the best predictor of neonatal thrombocytopenia 
[16]. Regardless, other studies detected that severity of 
maternal thrombocytopenia is not a predictive factor for 
neonatal thrombocytopenia [6, 17]. 
Table 3. The impact of severe gestational thrombocytopenia on the perinatal outcome and incidence of neonatal thrombocytopenia
Possible predictors OR 95% CI P-value
Maternal platelet count 0.960 0.918–1.01 0.071
Delivery mode 0.698 0.369–19.73 0.328
Gestational age 0.778 0.441–1.37 0.385
Birth weight 0.999 0.998–1.01 0.314
Apgar of < 7 at 1 min. 15.667 1.09–224.37 0.043
Neonatal acidosis (pH < 7.20) 15 0.74–303.74 0.078
Thrombocytopenia in previous pregnancy 7.33 0.51–105.92 0.144
Infection during pregnancy 11 1.36–88.87 0.24
OR — odds ratio; CI — confidence interval
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Thrombocytopenia is not usually considered as an indi-
cation for cesarean delivery and most studies recommend 
vaginal delivery, as long as there are no other obstetric indi-
cations present, even though neonates with severe throm-
bocytopenia may experience bleeding complications, espe-
cially intracranial hemorrhage, particularly as a consequence 
of head trauma during vaginal delivery. Ying-Hsuan et al. 
[18], analyzed 18,384 pregnancies and 787 of them (4.3%) 
were complicated by thrombocytopenia. They found that 
thrombocytopenic women had a significantly higher rate 
of cesarean delivery as compared to their health peers. In 
our study, pregnancies with gestational thrombocytopenia 
had a higher general rate of cesarean delivery, although 
the difference was not statistically significant, and with no 
neonatal complications. 
Several studies demonstrated that the risk of fetal intra-
cranial hemorrhage in infants born to mothers with immune 
thrombocytopenia is also very low [5]. No studies have yet 
confirmed that the risk is increased during vaginal delivery. 
Provan et al. [19], suggest that the mode of delivery in preg-
nant patients with immune thrombocytopenia should be 
dictated solely by maternal indications, and the fetal platelet 
count not be routinely determined. 
However, our study pointed that women with gesta-
tional thrombocytopenia at delivery had favorable perinatal 
outcomes, similarly to patients with a normal platelet count. 
A platelet count of > 50 × 109/L is generally considered 
safe for delivery (vaginal or cesarean) [20, 21]. We found 
placental abruption in 1 patient from the study group (2%) 
and 1 patient with severe postpartum hemorrhage (2%), 
without neonatal complications, as compared to Dwivedi 
et al. [11], who detected 4.2% of postpartum hemorrhage 
and 2.4% of placental abruption cases in women with ges-
tational thrombocytopenia. To the best of our knowledge, 
there are no long-term follow-up studies of women with 
gestational thrombocytopenia to determine if they have 
persistent thrombocytopenia. 
It is known that system virus infections may cause throm-
bocytopenia by direct bone marrow suppression or increased 
peripheral platelet consumption. In our study, positive urine 
culture and vaginal bacterial infection were found in 8 pa-
tients from the study group (16%). Parnas et al. [20], noted 
higher rates of Apgar scores of < 7 at 5 min. in infants born 
to mothers with thrombocytopenia versus healthy women 
(p = 0.001), intrauterine growth restriction (p = 0.003), and 
stillbirth (p < 0.001). Our results did not confirm their findings, 
probably because of our exclusion criteria. 
Analyzing the possible risk factors for predicting neo-
natal thrombocytopenia in patients with severe gestational 
thrombocytopenia, we found maternal platelet count to be 
important but not significant (Table 3). We used corticosteroid 
therapy in 7 patients from the study group. Four patients 
(33.3%) had severe gestational thrombocytopenia. We had 
no need for intravenous immunoglobulin (IVIG). Kasai et al. 
[22], found that maternal treatment was required in 80% 
of immune thrombocytopenia subjects, but in none of the 
women with gestational thrombocytopenia, and the preg-
nancy outcomes were favorable in both groups, with no need 
for fetal treatment. Gernsheimer et al. [21], recommend the 
use of corticosteroids or IVIG if platelet count falls below 20– 
–30 × 109/L. Some studies consider the following as important 
predictors of an increased risk of neonatal thrombocytopenia: 
maternal history of splenectomy, maternal platelet count 
of < 50 × 109/L at some point during the pregnancy, and 
a previous pregnancy complicated with neonatal thrombocy-
topenia [23–26]. Noris et al. [27], performed a multicenter, ret-
rospective study evaluating 339 pregnancies in 181 women. 
In their study, very early preterm deliveries, the lowest birth 
weight, the lowest Apgar scores, the greatest number with 
serious post-partum hemorrhage (> 500  mL) were reported 
only in severely thrombocytopenic women. Also, the use of 
regional analgesia/anesthesia was the lowest, and the rate 
of cesarean sections was the highest in that group [28]. In 
their study, Aiyelaagabe et al. [29] reported 215 women with 
a platelet count of ≤ 120 × 109/L during pregnancy, and found 
that maternal platelet count did not correlate with either 
blood loss or neonatal platelet count. 
According to our data, pregnancies with moderate or 
severe gestational thrombocytopenia, as compared to the 
control group, were not at a higher risk of cesarean section, 
intrauterine fetal death, preterm delivery, low Apgar scores, 
higher admission to the NICU rate, intracranial hemorrhage, 
neonatal death, or adverse maternal outcome.
CONCLUSIONS
Since gestational thrombocytopenia is usually mild or 
moderate, our data confirm that even severe gestational 
thrombocytopenia is not associated with adverse maternal 
or neonatal outcome. Also, moderate neonatal thrombocy-
topenia is more common in pregnancies complicated with 
severe gestational thrombocytopenia and the incidence 
of severe gestational thrombocytopenia is more frequent 
in patients with thrombocytopenia in previous pregnancy.
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